Cyclosporin A (Neoral) in pediatric organ transplantation

Pediatric Transplantation

Volumn 2, Issue 1, 1998, Pages 35-39

  Hoyer, Peter F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclosporin A; Neoral; Pediatric organ transplantation; Sandimmune

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

CHILD; COMPARATIVE STUDY; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METABOLISM; REVIEW; TREATMENT OUTCOME;

CHILD; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031988020     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. SALLAS WM. Pharmacokinetic and statistical comparisons of two formulations of cyclosporine in childen. Neoral in pediatric transplantation, round table discussion 1996, Madrid.
2. DUNN S, COONEY G, SOMMERAUER J, et al. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation 1997: 63: 1762-1767.
3. ETTENGER RE, SMITH HT, KAISER R, et al. Use of Neoral in paediatric renal transplantation. Transplant Proc 1996: 28: 2257-2258
4. COONEY GF, LUM BL, MELIGENI JA, DUNN SP. Pharmacokinetics of microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Transplant Proc 1996: 28: 2270-2272.
5. HOLMBERG C, LAINE J, JALANKO H, LEIJALA M, HOPPU K. Conversion from cyclosporine to Neoral in paediatric recipients for kidney, liver and heart transplantation. Transplant Proc 1996: 28: 2262-2263.
6. HOPPU K, JALANKO H, LAINE H, HOLMBERG C. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. Transplantation 1996: 62: 66-71.
7. D'AGOSTINO D, GIMENEZ M, YAMAGUCHI B, GLANCSZPIGEL R, VINUESA F, GAMBA M. Conversion and pharmacokinetic studies of Sandimmun Neoral in paediatric liver transplant patient. Transplantation 1997 (in press).
8. YEE GC, LENNON TP, GMUR DJ, KENNEDY MS, DEEG HJ. Age dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986: 40: 438-443.
9. BURCKART GJ, VENKATARAMANAN R, STARZL TE, PTACHEINSKI RJ, GARTNER CJ, ROSENTHAL T. Cyclosporine clearance in children following organ transplantation. J Clin Pharmacol 1984: 24: 412-416.
10. HOYER PF, BRODEHL J, EHRICH JHH, OFFNER G. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 1991: 5: 630-638.
11. NOBLE S, MARKHAM A. Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995: 50: 951.
12. VONDERSCHER J, MAINZER A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994: 26: 2925-2927.
13. KAHAN BD, DUNN J, FITTS C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant patients. In: KAHAN BD, ed. Cyclosporine, the ten-year experience. Norwalk, CT: Appleton & Lange, 1994: 2940.
14. KOVARIK JM, MUELLER EA, VAN Bree JB, ARNS W, RENNER E, KUTZ K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994: 16: 232-237.
15. KOVARIK JM, MUELLER EA, RICHARD F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996: 623: 759-763.
16. WAHLBERG J, WILCZEK HE, FAUCHALD P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995: 60: 648-652.
17. KOVARIK JM, MUELLER EA, VAN Bree JV, TETZLOFF W, KUTZ K. Reduced inter- and intraindividuel variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994: 83: 444-446.
18. KAHAN BD, WELSH M, SCHOENBERG L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantaion 1996: 62: 599-606.
19. TAESCH S, NIESE D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmune Neoral, in renal transplant patients. Transplant Int 1994: 7 (suppl 1): 263-266.
20. NIESE D. A double-blind randomized study of Sandimmune Neoral versus Sandimmune in new renal transplant recipients: results after 12 months. Transplant Proc 1995: 27: 1849-1956.
21. KOVARIK JM, MUELLER EA, VAN Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994: 58: 658-663.
22. LAINE J, HOPPU K, JALANKO H, RÖNNHOLM K, HOLMBERG C. Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts. Transplantation 1997: 63: 1768-1772.
23. HOYER PF, BOEKENKAMP A, VESTER U, OFFNER G, BRODEHL J. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc 1996: 28: 2259-2261.
24. MORRISON D. Multivariate Statistical Methods. 2nd edn. New York: McGraw-Hill, 1976: 250.